Education
About Us
Working with TipRanks
Follow Us
Biomarin Pharmaceutical Inc. (BMRN)
:BMRN
BMRN Stock Chart & Stats
$53.40
$0.93(1.37%)
At close: 4:00 PM EST
$53.40
$0.93(1.37%)
Day’s Range― - ―
52-Week Range$50.76 - $73.51
Previous CloseN/A
Volume465.01K
Average Volume (3M)3.09M
Market Cap
$10.26B
Enterprise Value$9.53B
Total Cash (Recent Filing)$1.48B
Total Debt (Recent Filing)$596.66M
Price to Earnings (P/E)20.0
Beta0.47
Next Earnings
Feb 25, 2026EPS Estimate
0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding192,114,350
10 Day Avg. Volume3,544,754
30 Day Avg. Volume3,090,769
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.21
Price to Sales (P/S)4.38
P/FCF Ratio26.27
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue3.08
Enterprise Value/Gross Profit3.79
Enterprise Value/Ebitda12.34
Forecast
1Y Price Target
$85.88Price Target Upside60.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)2.8
Revenue Forecast (FY)$3.17B
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentBioMarin's key pipeline drug BMN333 is on track for Phase 2/3 trials, with confidence that it will outperform its competitor in Phase 3, indicating potential future market leadership.
Regulatory ApprovalsThe FDA has accepted the supplemental Biologics License Application for Palynziq, aiming to expand its use to adolescent PKU patients, highlighting regulatory progress and potential market growth.
Revenue ProjectionsBioMarin raised the lower bound of its 2025 revenue guidance from $3.125 billion to $3.150 billion, signaling confidence in financial growth.
Bears Say
Competitive PressureThe commercialization of PTC Therapeutics’ Sephience, with its daily oral formulation and superior safety profile, could limit the initial uptake in the adolescent patient population, impacting BioMarin's enzyme therapies growth.
Financial PerformanceBioMarin reported a topline miss for the third quarter with Voxzogo revenue coming in light versus estimates and down slightly quarter-over-quarter, indicating challenges in achieving financial targets.
Guidance RevisionsManagement withdrew the $4 billion 2027 revenue guidance, noting it was likely too high, suggesting potential challenges in meeting long-term financial goals.
BioMarin Pharmaceutical News
BMRN FAQ
What was Biomarin Pharmaceutical Inc.’s price range in the past 12 months?
Biomarin Pharmaceutical Inc. lowest stock price was $50.76 and its highest was $73.51 in the past 12 months.
What is Biomarin Pharmaceutical Inc.’s market cap?
Biomarin Pharmaceutical Inc.’s market cap is $10.26B.
When is Biomarin Pharmaceutical Inc.’s upcoming earnings report date?
Biomarin Pharmaceutical Inc.’s upcoming earnings report date is Feb 25, 2026 which is in 79 days.
How were Biomarin Pharmaceutical Inc.’s earnings last quarter?
Biomarin Pharmaceutical Inc. released its earnings results on Oct 27, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.12.
Is Biomarin Pharmaceutical Inc. overvalued?
According to Wall Street analysts Biomarin Pharmaceutical Inc.’s price is currently Undervalued.
Does Biomarin Pharmaceutical Inc. pay dividends?
Biomarin Pharmaceutical Inc. does not currently pay dividends.
What is Biomarin Pharmaceutical Inc.’s EPS estimate?
Biomarin Pharmaceutical Inc.’s EPS estimate is 0.81.
How many shares outstanding does Biomarin Pharmaceutical Inc. have?
Biomarin Pharmaceutical Inc. has 192,114,350 shares outstanding.
What happened to Biomarin Pharmaceutical Inc.’s price movement after its last earnings report?
Biomarin Pharmaceutical Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 1.557%.
Which hedge fund is a major shareholder of Biomarin Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in BMRN
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$85.88 (60.82% Upside)
$85.88 (60.82% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.28%
12-Months-Change
Fundamentals
Return on Equity
9.07%
Trailing 12-Months
Asset Growth
11.15%
Trailing 12-Months
Company Description
Biomarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BMRN Company Deck
BMRN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted BioMarin's strong revenue growth, particularly with VOXZOGO and enzyme therapies, alongside a solid cash position and operational efficiency. However, challenges included a significant IPR&D charge, the decision to divest ROCTAVIAN, and enzyme therapy revenue fluctuations. While there are notable achievements, the presence of significant lowlights balances the overall sentiment.View all BMRN earnings summariesBMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
$85.88
▲(60.82% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Summit Therapeutics
―
Immunovant
―
Ownership Overview
0.45% Insiders
30.55% Mutual Funds
27.10% Other Institutional Investors
19.35% Public Companies and Individual Investors